0001428336-20-000010.txt : 20200316 0001428336-20-000010.hdr.sgml : 20200316 20200316160824 ACCESSION NUMBER: 0001428336-20-000010 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200316 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200316 DATE AS OF CHANGE: 20200316 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEALTHEQUITY, INC. CENTRAL INDEX KEY: 0001428336 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36568 FILM NUMBER: 20717179 BUSINESS ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 BUSINESS PHONE: 801-727-1000 MAIL ADDRESS: STREET 1: 15 WEST SCENIC POINTE DRIVE STREET 2: SUITE 100 CITY: DRAPER STATE: UT ZIP: 84020 FORMER COMPANY: FORMER CONFORMED NAME: HEALTHEQUITY INC DATE OF NAME CHANGE: 20080227 8-K 1 hqy-20200316.htm 8-K hqy-20200316
0001428336false00014283362020-03-162020-03-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

March 16, 2020

HEALTHEQUITY, INC.


Delaware
001-36568
52-2383166
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)

15 West Scenic Pointe Drive
Suite 100
Draper, Utah 84020
(801) 727-1000

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareHQYThe NASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 2.02 Results of Operations and Financial Condition

On March 16, 2020, HealthEquity, Inc. issued a press release attached as Exhibit 99.1 to this current report on Form 8-K.

The information in Exhibit 99.1 is being furnished to the Securities and Exchange Commission and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTHEQUITY, INC.
Date: March 16, 2020By:/s/ Darcy Mott
Name:Darcy Mott
Title:Executive Vice President and Chief Financial Officer


EX-99.1 2 hqyq4fy20earningsrelea.htm EX-99.1 Document

HealthEquity Reports Fourth Quarter and Fiscal Year Ended January 31, 2020 Financial Results
Highlights of the fiscal year include:
Revenue of $532.0 million, an increase of 85% compared to $287.2 million in FY19.
Net income of $39.7 million, compared to $73.9 million in FY19, with non-GAAP net income of $118.4 million, compared to $81.8 million in FY19.
Net income per diluted share of $0.58, compared to $1.17 in FY19, with non-GAAP net income per diluted share of $1.73, compared to $1.29 in FY19.
Adjusted EBITDA of $196.5 million, compared to $118.4 million in FY19.
5.3 million HSAs, an increase of 34% compared to FY19.
$11.5 billion Total HSA Assets, an increase of 43% compared to FY19.
12.8 million Total Accounts, including both HSAs and complementary consumer-directed benefit ("CDB") accounts.
The WageWorks acquisition closed on August 30, 2019.
Highlights of the fourth quarter include:
Revenue of $201.2 million, an increase of 166% compared to $75.8 million in Q4 FY19.
Net loss of $0.2 million, compared to net income of $13.1 million in Q4 FY19, with non-GAAP net income of $27.9 million, compared to $18.9 million in Q4 FY19.
Net loss per diluted share of less than one-half of one cent, compared to net income per diluted share of $0.21 in Q4 FY19, with non-GAAP net income per diluted share of $0.39, compared to $0.30 in Q4 FY19.
Adjusted EBITDA of $61.3 million, compared to $27.3 million in Q4 FY19.
Draper, Utah – March 16, 2020 – HealthEquity, Inc. (NASDAQ: HQY) ("HealthEquity" or the "Company"), the nation's largest health savings account ("HSA") non-bank custodian, today announced financial results for its fourth quarter and fiscal year ended January 31, 2020.
“The HealthEquity team delivered a strong fourth quarter to cap another record-setting year of growth in fiscal 2020, while also accelerating the WageWorks integration. Revenue for the full year increased 85% to $532 million, while driving Adjusted EBITDA growth 66% to $196 million – both record highs,” said Jon Kessler, President and CEO of HealthEquity. “More importantly, we have entered fiscal year 2021 with momentum in HSA growth, taking a larger share of the market than ever before.”
Fiscal year financial results
Revenue for the fiscal year ended January 31, 2020 of $532.0 million grew 85% compared to $287.2 million for the fiscal year ended January 31, 2019, and 21% excluding the impact of the WageWorks acquisition and related realized net synergies. Revenue this year included: service revenue of $262.9 million, custodial revenue of $181.9 million, and interchange revenue of $87.2 million.
HealthEquity reported net income of $39.7 million, or $0.58 per diluted share, and non-GAAP net income of $118.4 million, or $1.73 per diluted share, for the fiscal year ended January 31, 2020. The Company reported net income of $73.9 million, or $1.17 per diluted share, and non-GAAP net income of $81.8 million, or $1.29 per diluted share, for the fiscal year ended January 31, 2019.
Adjusted EBITDA of $196.5 million for the fiscal year ended January 31, 2020 grew 66% compared to $118.4 million for the fiscal year ended January 31, 2019. Adjusted EBITDA was 37% of revenue compared to 41% for the fiscal year ended January 31, 2019.
As of January 31, 2020, HealthEquity had $191.7 million of cash and cash equivalents and $1.22 billion of outstanding debt, net of issuance costs. This compares to $361.5 million in cash and cash equivalents and no outstanding debt as of January 31, 2019.
Fourth quarter financial results
Revenue for the fourth quarter ended January 31, 2020 of $201.2 million grew 166% compared to $75.8 million for the fourth quarter ended January 31, 2019, and 17% excluding the impact of the WageWorks acquisition and related realized net synergies. Revenue this quarter included: service revenue of $122.2 million, custodial revenue of $49.3 million, and interchange revenue of $29.7 million.



HealthEquity reported a net loss of $0.2 million, or less than one-half of one cent per diluted share, and non-GAAP net income of $27.9 million, or $0.39 per diluted share, for the fourth quarter ended January 31, 2020. The Company reported net income of $13.1 million, or $0.21 per diluted share, and non-GAAP net income of $18.9 million, or $0.30 per diluted share, for the fourth quarter ended January 31, 2019.
Adjusted EBITDA was $61.3 million for the fourth quarter ended January 31, 2020, an increase of 125% compared to $27.3 million for the fourth quarter ended January 31, 2019. Adjusted EBITDA was 30% of revenue compared to 36% for the fourth quarter ended January 31, 2019.
Account and asset metrics
HSAs as of January 31, 2020 exceeded 5.3 million, an increase of 34% year over year, or 15% excluding acquired HSAs. Active HSAs were 4.3 million, up 34% from one year ago, including 220,000 HSAs with investments, an increase of 35% year over year. Total Accounts as of January 31, 2020 reached 12.8 million, including 7.4 million CDBs, including 6.8 million from the WageWorks acquisition.
Total HSA Assets as of January 31, 2020 were $11.5 billion, an increase of 43% year over year, or 22% excluding acquired HSA assets. Total HSA assets included $8.7 billion of HSA cash and $2.8 billion of HSA investment assets. Client-held funds, which are pre-funds held on behalf of our Clients to facilitate administration of our CDBs, and from which we generate custodial revenue, were $779.0 million as of January 31, 2020, including approximately $632.0 million from the WageWorks acquisition.
New HSA openings and HSA asset growth
HealthEquity reported sales of 724,000 new HSAs in the year ended January 31, 2020, 7% more than in the previous fiscal year. HSA members grew their balances by approximately $1.7 billion during the year, a 35% increase year over year, reflecting both large net inflows and positive market results.
WageWorks closing and integration
HealthEquity completed its acquisition of WageWorks on August 30, 2019.  We aim to achieve our previously stated goal of a run rate of $50 million of net synergies by the end of fiscal 2021. We have continued to make progress on commitments to WageWorks clients, and expect to complete the on-shoring of all telephone-based member services to the United States during the second quarter of fiscal 2021.
Business outlook
For the fiscal year ending January 31, 2021, we expect our revenue to be between $770 million and $790 million. Our outlook for net loss is a range of $14 million to $4 million, resulting in a net loss per diluted share range of $0.19 to $0.05. Our Adjusted EBITDA outlook is a range of $245 million to $255 million. We also expect our non-GAAP net income, calculated using the updated method described below, to be in a range between $124 million and $132 million. Our non-GAAP net income outlook, results in a non-GAAP net income per diluted share range between $1.70 and $1.81 (based on an estimated 73 million weighted-average shares outstanding).
See “Non-GAAP financial information” below for definitions of our Adjusted EBITDA and non-GAAP net income. A reconciliation of the non-GAAP financial measures used throughout this release to the most comparable GAAP financial measures is included with the financial tables at the end of this release.
Conference call
HealthEquity management will host a conference call at 4:30 pm (Eastern Time) on Monday, March 16, 2020 to discuss the fiscal year 2020 fourth quarter and fiscal year financial results. The conference call will be accessible by dialing 844-791-6252, or 661-378-9636 for international callers, and referencing conference ID 2567145. A live audio webcast of the call will also be available on the investor relations section of our website at http://ir.healthequity.com.
Non-GAAP financial information
To supplement our financial information presented on a GAAP basis, we disclose non-GAAP financial measures, including Adjusted EBITDA, non-GAAP net income, and non-GAAP net income per diluted share.
Adjusted EBITDA is adjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration and acquisition-related costs, gains and losses on marketable equity securities, and other certain non-operating items.



Non-GAAP net income is calculated by adding back to GAAP net income amortization of acquired intangible assets, stock-based compensation expense, and integration and acquisition-related costs, net of an estimated statutory tax rate, subtracting the excess tax benefits due to the adoption of ASU 2016-09, and adjusting for gains and losses on marketable equity securities, net of an estimated statutory tax rate. In response to feedback received from investors, the Company will use an updated method for calculating non-GAAP net income beginning in fiscal year 2021. The updated method will summarize the effect of a non-GAAP income tax provision in a single line item, rather than presenting each non-GAAP adjustment net of the related tax effect. For comparison, separate reconciliations of non-GAAP net income have been provided in the tables below using the current method and the updated method.
Non-GAAP net income per diluted share is calculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.
Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP and should not be considered as a substitute for, or superior to, GAAP results. We believe that these non-GAAP financial measures provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company cautions investors that non-GAAP financial information, by its nature, departs from GAAP; accordingly, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies. In addition, while amortization of acquired intangible assets is being excluded from non-GAAP net income, the revenue generated from those acquired intangible assets is not excluded. Whenever we use these non-GAAP financial measures, we provide a reconciliation of the applicable non-GAAP financial measure to the most closely applicable GAAP financial measure. Investors are encouraged to review the related GAAP financial measures and the reconciliation of the non-GAAP financial measures to their most directly comparable GAAP financial measure as detailed in the tables below.
About HealthEquity
HealthEquity administers Health Savings Accounts (HSAs) and other consumer-directed benefits for our more than 12 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.
Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.
Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:
our ability to realize the anticipated financial and other benefits from combining the operations of WageWorks with our business in an efficient and effective manner;
our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
our dependence on the continued availability and benefits of tax-advantaged health savings accounts and other consumer-directed benefits;
our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
the significant competition we face and may face in the future, including from those with greater resources than us;



our reliance on the availability and performance of our technology and communications systems;
recent and potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
our ability to comply with current and future privacy, healthcare, tax, investment adviser and other laws applicable to our business;
our reliance on partners and third party vendors for distribution and important services;
our ability to develop and implement updated features for our technology and communications systems and successfully manage our growth;
our ability to protect our brand and other intellectual property rights; and
our reliance on our management team and key team members.
For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our most recent Quarterly Report on Form 10-Q and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact
Richard Putnam
801-727-1209
rputnam@healthequity.com





HealthEquity, Inc. and its subsidiaries
Consolidated balance sheets (unaudited)
(in thousands, except par value)January 31, 2020January 31, 2019
Assets
Current assets
Cash and cash equivalents$191,726  $361,475  
Accounts receivable, net of allowance for doubtful accounts of $1,216 and $125 as of January 31, 2020 and 2019, respectively70,485  25,668  
Other current assets33,793  7,534  
Total current assets296,004  394,677  
Property and equipment, net33,486  8,223  
Operating lease right-of-use assets83,178  —  
Intangible assets, net783,279  79,666  
Goodwill1,334,127  4,651  
Deferred tax asset18  1,677  
Other assets35,089  21,122  
Total assets$2,565,181  $510,016  
Liabilities and stockholders’ equity
Current liabilities
Accounts payable$3,980  $3,520  
Accrued compensation50,121  16,981  
Accrued liabilities46,572  8,552  
Current portion of long-term debt39,063  —  
Operating lease liabilities12,401  —  
Total current liabilities152,137  29,053  
Long-term liabilities
Long-term debt, net of issuance costs1,181,615  —  
Operating lease liabilities, non-current68,017  —  
Other long-term liabilities2,625  2,968  
Deferred tax liability130,492  916  
Total long-term liabilities1,382,749  3,884  
Total liabilities1,534,886  32,937  
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.0001 par value, 100,000 shares authorized, no shares issued and outstanding as of January 31, 2020 and 2019—  —  
Common stock, $0.0001 par value, 900,000 shares authorized, 71,051 and 62,446 shares issued and outstanding as of January 31, 2020 and 2019, respectively  
Additional paid-in capital818,774  305,223  
Accumulated earnings211,514  171,850  
Total stockholders’ equity1,030,295  477,079  
Total liabilities and stockholders’ equity$2,565,181  $510,016  




HealthEquity, Inc. and its subsidiaries
Consolidated statements of operations and comprehensive income (loss) (unaudited)
Three months ended January 31,Year ended January 31,
(in thousands, except per share data)2020201920202019
Revenue
   Service revenue$122,158  $25,767  $262,868  $100,564  
   Custodial revenue49,354  35,465  181,892  126,178  
   Interchange revenue29,688  14,545  87,233  60,501  
   Total revenue201,200  75,777  531,993  287,243  
 Cost of revenue
   Service costs78,191  24,050  170,863  76,858  
   Custodial costs4,847  3,632  17,563  14,124  
   Interchange costs4,481  3,650  17,658  15,068  
   Total cost of revenue87,519  31,332  206,084  106,050  
 Gross profit113,681  44,445  325,909  181,193  
 Operating expenses
   Sales and marketing13,936  7,893  43,951  29,498  
   Technology and development31,515  10,002  77,576  35,057  
   General and administrative23,368  8,478  60,561  33,039  
   Amortization of acquired intangible assets18,668  1,491  34,704  5,929  
Merger integration11,652  —  32,111  —  
   Total operating expenses99,139  27,864  248,903  103,523  
 Income from operations14,542  16,581  77,006  77,670  
 Other expense
Interest expense(14,417) (66) (24,772) (270) 
   Other expense, net(732) (155) (9,079) (1,582) 
 Total other expense(15,149) (221) (33,851) (1,852) 
 Income (loss) before income taxes(607) 16,360  43,155  75,818  
 Income tax provision (benefit)(417) 3,241  3,491  1,919  
 Net income (loss) and comprehensive income (loss)$(190) $13,119  $39,664  $73,899  
Net income (loss) per share:
 Basic$0.00  $0.21  $0.59  $1.20  
 Diluted$0.00  $0.21  $0.58  $1.17  
Weighted-average number of shares used in computing net income (loss) per share:
 Basic70,880  62,183  67,026  61,836  
 Diluted70,880  63,723  68,453  63,370  




HealthEquity, Inc. and its subsidiaries
Consolidated statements of cash flows (unaudited)
Year ended January 31,
(in thousands)202020192018
 Cash flows from operating activities:
 Net income$39,664  $73,899  $47,362  
 Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization55,352  18,185  15,952  
Stock-based compensation39,844  21,057  14,310  
(Gains) losses on marketable equity securities and other(23,151) 1,173  597  
Deferred taxes3,665  408  4,306  
 Changes in operating assets and liabilities:
Accounts receivable(6,127) (4,306) (4,734) 
Other assets (11,659) (5,893) (760) 
Operating lease right-of-use assets6,218  —  —  
Accounts payable(3,839) 863  (581) 
Accrued compensation4,550  4,432  3,827  
Accrued liabilities and other current liabilities6,806  3,031  484  
Operating lease liabilities, non-current(5,383) —  —  
Other long-term liabilities(83) 573  939  
 Net cash provided by operating activities105,857  113,422  81,702  
 Cash flows from investing activities:
Acquisitions, net of cash acquired(1,647,425) —  (2,882) 
Purchases of marketable securities(53,845) (728) (483) 
Purchases of property and equipment(7,286) (3,869) (5,458) 
Purchases of software and capitalized software development costs(25,654) (9,978) (10,380) 
Acquisition of intangible member assets(9,134) (1,195) (17,545) 
Proceeds from sale of marketable securities—  41,422  —  
 Net cash provided by (used in) investing activities(1,743,344) 25,652  (36,748) 
 Cash flows from financing activities:
Proceeds from long-term debt1,250,000  —  —  
Payment of debt issuance costs(30,504) —  —  
Principal payments on long-term debt(7,813) —  —  
Settlement of client-held funds obligation(213,787) —  —  
Proceeds from follow-on offering, net of payments for offering costs458,495  —  —  
Proceeds from exercise of common stock options11,347  22,929  14,564  
 Net cash provided by financing activities1,467,738  22,929  14,564  
 Increase (decrease) in cash and cash equivalents(169,749) 162,003  59,518  
 Beginning cash and cash equivalents361,475  199,472  139,954  
 Ending cash and cash equivalents$191,726  $361,475  $199,472  



Stock-based compensation expense (unaudited)
Total stock-based compensation expense included in the consolidated statements of operations and comprehensive income (loss) is as follows:
Three months ended January 31,Year ended January 31,
(in thousands)2020201920202019
Cost of revenue$1,507  $829  $4,792  $2,837  
Sales and marketing1,225  950  4,694  3,536  
Technology and development2,049  1,440  7,649  5,117  
General and administrative3,486  2,377  12,972  9,567  
Merger integration383  —  1,603  —  
Other expense, net—  —  13,714  —  
Total stock-based compensation expense$8,650  $5,596  $45,424  $21,057  
Total Accounts (unaudited)
% change from  
(in thousands, except percentages)January 31, 2020January 31, 20192019 to 2020  
HSAs5,344  3,994  34 %
Average HSAs - Year-to-date4,517  3,608  25 %
Average HSAs - Quarter-to-date5,179  3,813  36 %
New HSAs from Sales - Year-to-date724  674  %
New HSAs from Acquisitions - Year-to-date757   n/a  
New HSAs from Sales - Quarter-to-date379  341  11 %
Active HSAs4,348  3,241  34 %
HSAs with investments220  163  35 %
CDBs7,437  572  n/a  
Total Accounts12,781  4,566  180 %
Average Total Accounts - Year-to-date8,013  4,194  91 %
Average Total Accounts - Quarter-to-date12,603  4,402  186 %
HSA assets (unaudited)
% change from
(in millions, except percentages)January 31, 2020January 31, 20192019 to 2020  
HealthEquity HSA cash (custodial revenue) (1)$7,244  $6,428  13 %
WageWorks HSA cash (custodial revenue) (2)1,057  —  n/a  
WageWorks HSA cash (no custodial revenue) (3)383  —  n/a  
Total HSA cash8,684  6,428  35 %
HealthEquity HSA investments (custodial revenue) (1)2,495  1,670  49 %
WageWorks HSA investments (no custodial revenue) (3)362  —  n/a  
Total HSA investments2,857  1,670  71 %
Total HSA Assets11,541  8,098  43 %
Average daily HealthEquity HSA cash - Year-to-date6,523  5,586  17 %
Average daily HealthEquity HSA cash - Quarter-to-date$6,788  $5,837  16 %
(1) HSA Assets administered by HealthEquity that generate custodial revenue. These amounts exclude HSA Assets administered by WageWorks.
(2) HSA Assets administered by WageWorks that generate custodial revenue.
(3) HSA Assets administered by WageWorks that do not generate custodial revenue.




Client-held funds (unaudited)
% change from
(in millions, except percentages)January 31, 2020January 31, 20192019 to 2020  
Client-held funds (custodial revenue) (1)$779,000  $—  n/a  
Average daily Client-held funds - Year-to-date (1)382,000  —  n/a  
Average daily Client-held funds - Quarter-to-date (1)$727,000  $—  n/a  
(1) Client-held funds that generate custodial revenue. The Company did not have material Client-held funds prior to the WageWorks acquisition.
Net income (loss) reconciliation to Adjusted EBITDA (unaudited)
Three months ended January 31,Year ended January 31,
(in thousands)2020201920202019
Net income (loss)$(190) $13,119  $39,664  $73,899  
Interest income(632) (1,027) (5,905) (1,946) 
Interest expense14,417  66  24,772  270  
Income tax provision (benefit)(417) 3,241  3,491  1,919  
Depreciation and amortization7,708  3,196  20,648  12,256  
Amortization of acquired intangible assets18,668  1,491  34,704  5,929  
Stock-based compensation expense8,267  5,596  30,107  21,057  
Merger integration expenses (1)11,652  —  32,111  —  
Acquisition costs (2)98  1,047  40,810  2,121  
(Gain) loss on marketable equity securities(190) (19) (27,760) 102  
Other (3)1,957  578  3,811  2,775  
Adjusted EBITDA$61,338  $27,288  $196,453  $118,382  
(1)Includes $1.6 million of stock-based compensation expense related to post-acquisition integration activities.
(2)Includes $13.7 million of stock-based compensation expense related to acquisition-related cash and equity accelerations.
(3)For the fiscal years ended January 31, 2020 and 2019, Other consisted of amortization of incremental costs to obtain a contract of $1.9 million and $1.5 million, and other costs of $1.9 million and $1.3 million, respectively. For the three months ended January 31, 2020 and 2019, Other consisted of amortization of incremental costs to obtain a contract of $0.5 million and $0.4 million, and other costs of $1.5 million and $0.2 million, respectively.
Reconciliation of net income outlook to Adjusted EBITDA outlook (unaudited)
Outlook for the year ending
(in millions)January 31, 2021
Net loss$(14) - (4) 
Interest income~(1) 
Interest expense~39  
Income tax benefit~(3) 
Depreciation and amortization~39  
Amortization of acquired intangible assets~74  
Stock-based compensation expense~48  
Merger integration expenses~60  
Other~3  
Adjusted EBITDA$245 - 255  








Reconciliation of net income to non-GAAP net income (unaudited)
Three months endedYear ended
(in millions, except per share data)January 31, 2020January 31, 2020
Net income (loss)$—  $40  
Amortization of acquired intangible assets, net of tax (1)14  26  
Stock-based compensation expense, net of tax (1) 23  
Excess tax benefit due to adoption of ASU 2016-09(1) (5) 
Merger integration expenses, net of tax (1) 24  
Acquisition costs, net of tax (1)—  31  
Gain on marketable equity securities, net of tax (1)—  (21) 
Non-GAAP net income$28  $118  
Diluted weighted-average shares72  68  
Non-GAAP net income per diluted share (2)$0.39  $1.73  
(1) For the three months and fiscal year ended January 31, 2020, the Company used an estimated statutory tax rate of 24% to calculate the net impact of non-GAAP adjustments to net income.
(2) Non-GAAP net income per diluted share may not calculate due to rounding of non-GAAP net income and diluted weighted-average shares.
Reconciliation of net income to non-GAAP net income - Method to be used for future periods (unaudited)
Three months endedYear endedOutlook for the year ending
(in millions, except per share data)January 31, 2020January 31, 2020January 31, 2021
Net income (loss)$—  $40  $(14) - (4) 
Income tax provision (benefit)(1)  ~(3) 
 Income (loss) before income tax provision (benefit) - GAAP(1) 43  (17) - (7) 
Non-GAAP adjustments:
Amortization of acquired intangible assets19  35  ~74  
Stock-based compensation expense 30  ~48  
Merger integration expenses12  32  ~60  
Acquisition costs—  41  —  
Gain on marketable equity securities—  (28) —  
Total adjustments to GAAP income before income tax provision39  110  ~178  
Income before income tax provision - Non-GAAP38  153  165 - 175  
Income tax provision - Non-GAAP (1)10  38  41 - 43  
Non-GAAP net income - Method to be used for future periods$28  $115  $124 - 132  
Diluted weighted-average shares72  68  73  
Non-GAAP net income per diluted share (2)$0.39  $1.68  $1.70 - 1.81  
(1) The Company utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations. The normalized non-GAAP tax rate applied to each period presented was 25%. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occur that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.
(2) Non-GAAP net income per diluted share may not calculate due to rounding of non-GAAP net income and diluted weighted-average shares.








Certain terms
TermDefinition
HSAA financial account through which consumers spend and save long-term for healthcare on a tax-advantaged basis.
CDBConsumer-directed benefits offered by employers, including flexible spending and health reimbursement arrangements (“FSAs” and “HRAs”), Consolidated Omnibus Budget Reconciliation Act (“COBRA”) administration, commuter and other benefits.
HSA memberConsumers with HSAs that we serve.
Active HSAsAn HSA that (i) is associated with a Network Partner or a Client, in each case as of the end of the applicable period; or (ii) has a custodial balance at any point during the previous twelve month period.
Total HSA AssetsHSA members' deposits with our federally insured custodial depository partners and custodial cash deposits invested in an annuity contract with our insurance company partner. Total HSA Assets also includes HSA members' investments in mutual funds through our custodial investment fund partner.
ClientOur employer clients.
Total AccountsThe sum of HSAs and CDBs on our platforms.
Client-held fundsPre-funds held on behalf of our Clients to facilitate administration of our CDBs
Network PartnerOur health plan partners, benefits administrators, and retirement plan recordkeepers.
Adjusted EBITDAAdjusted earnings before interest, taxes, depreciation and amortization, amortization of acquired intangible assets, stock-based compensation expense, merger integration and acquisition-related costs, gains and losses on marketable equity securities, and other certain non-operating items.
Non-GAAP net income
Calculated by adding back to net income the following items: amortization of acquired intangible assets, stock-based compensation expense, and merger integration and acquisition-related costs, net of an estimated statutory tax rate, subtracting the excess tax benefits due to the adoption of ASU 2016-09, and adjusting for gains and losses on marketable equity securities, net of an estimated statutory tax rate. Certain of these items were added to the definition at the time of the WageWorks acquisition. Fiscal year 2019 amounts have been updated to reflect the change in definition.
Non-GAAP net income - Method to be used for future periodsCalculated by adding back to net income before provision for income taxes the following items: amortization of acquired intangible assets, stock-based compensation expense, merger integration and acquisition-related costs, and gains and losses on marketable equity securities.
Non-GAAP net income per diluted shareCalculated by dividing non-GAAP net income by diluted weighted-average shares outstanding.


EX-101.SCH 3 hqy-20200316.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 hqy-20200316_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 hqy-20200316_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 hqy-20200316_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover page. Cover page. Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Amendment Flag Amendment Flag Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code Trading Symbol Trading Symbol Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 hqy-20200316_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page
Mar. 16, 2020
Cover page.  
Document Type 8-K
Document Period End Date Mar. 16, 2020
Entity File Number 001-36568
Entity Registrant Name HEALTHEQUITY, INC.
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 52-2383166
Entity Address, Address Line One 15 West Scenic Pointe Drive
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Draper
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84020
City Area Code 801
Local Phone Number 727-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol HQY
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001428336
Amendment Flag false
EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 hqy-20200316_htm.xml IDEA: XBRL DOCUMENT 0001428336 2020-03-16 2020-03-16 0001428336 false 8-K 2020-03-16 HEALTHEQUITY, INC. DE 001-36568 52-2383166 15 West Scenic Pointe Drive Suite 100 Draper UT 84020 801 727-1000 false false false false Common stock, par value $0.0001 per share HQY NASDAQ false XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://healthequity.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports hqy-20200316.htm hqy-20200316.xsd hqy-20200316_cal.xml hqy-20200316_def.xml hqy-20200316_lab.xml hqy-20200316_pre.xml hqyq4fy20earningsrelea.htm http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 14 0001428336-20-000010-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001428336-20-000010-xbrl.zip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end XML 15 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "hqy-20200316.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "hqy-20200316_cal.xml" ] }, "definitionLink": { "local": [ "hqy-20200316_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "hqy-20200316.htm" ] }, "labelLink": { "local": [ "hqy-20200316_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "hqy-20200316_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "hqy-20200316.xsd" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "hqy", "nsuri": "http://healthequity.com/20200316", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200316.htm", "contextRef": "ibcf85119b0e34ae6ac915a684f974db0_D20200316-20200316", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://healthequity.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "hqy-20200316.htm", "contextRef": "ibcf85119b0e34ae6ac915a684f974db0_D20200316-20200316", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page.", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://healthequity.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" }